ADHD Medicines: How Should Children's Growth

✓ Medically reviewed | Published: | Evidence level: 1A
Questions about psychiatric medicine safety in children highlight the importance of monitoring ADHD treatment. Stimulants can improve symptoms, while changes in appetite, sleep and growth require individualized follow-up, according to CDC and National Institute of Mental Health guidance.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pediatric Health

Quick Facts

Stimulant symptom response: CDC
70–80% have fewer symptoms
Children's height checks: NICE
Every 6 months
Weight checks, ages ≤10: NICE
Every 3 months

What benefits and side effects should families understand?

Quick answer: ADHD medicines can reduce symptoms, but appetite, sleep and everyday functioning should be reviewed alongside treatment benefits.

Public concern about psychiatric medicines for children raises a practical question for families managing attention-deficit/hyperactivity disorder: how can treatment benefits be preserved while side effects are addressed? The CDC reports that approximately 70–80% of children with ADHD experience fewer symptoms when taking stimulant medicines. That estimate describes symptom improvement; it does not mean every child responds equally or becomes symptom-free. The agency also identifies reduced appetite and difficulty sleeping as possible adverse effects. [CDC treatment guidance](https://www.cdc.gov/adhd/treatment/)

The National Institute of Mental Health explains that stimulants affect brain chemicals involved in attention and thinking. Treatment decisions also need to account for daily functioning, relationships and coexisting difficulties. Medication can be combined with parent training and school support, with adjustments based on the child's response. Monitoring should therefore ask both whether symptoms improve and whether the child is eating, sleeping and functioning well. [NIMH ADHD information](https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know)

How often should children taking ADHD medication have growth checks?

Quick answer: UK NICE guidance recommends height measurements every six months and weight checks at intervals determined by age and clinical concerns.

NICE recommends measuring weight every three months in children aged 10 or younger. For older children and adolescents, it recommends checks three and six months after treatment starts, followed by six-monthly measurements, with additional checks when concerns arise. Height and weight should be plotted on a growth chart and reviewed by the clinician responsible for treatment. These are UK guideline intervals; an individual care plan may require closer follow-up. [NICE monitoring recommendations](https://www.nice.org.uk/guidance/ng87/chapter/recommendations#maintenance-and-monitoring)

Monitoring also extends beyond growth. NICE recommends checking pulse and blood pressure around dose changes and at six-month intervals. Persistent appetite loss, sleep difficulties or changes in behavior deserve discussion even when ADHD symptoms have improved. Recording when problems occur can help families describe them at appointments and support a more useful review of benefits and adverse effects. [NICE treatment monitoring](https://www.nice.org.uk/guidance/ng87/chapter/recommendations#maintenance-and-monitoring)

Can treatment adjustments improve weight gain and height growth?

Quick answer: Some approaches can improve weight gain, but a randomized trial found that faster weight gain did not necessarily produce faster height growth.

A trial published in the Journal of the American Academy of Child & Adolescent Psychiatry in 2020 initially enrolled 230 children aged 5–12. Among participants whose body mass index subsequently declined, 71 entered a randomized comparison of closer growth monitoring, medication limited to school days, or an additional calorie supplement. Weight gain accelerated across the groups, but the primary comparison did not establish a significant difference between them. None of the approaches increased the rate of height growth during the evaluated period. [Waxmonsky and colleagues' randomized trial](https://pubmed.ncbi.nlm.nih.gov/31473291/)

The findings distinguish weight recovery from height recovery and cannot establish eventual adult height. The trial was funded by the National Institute of Mental Health; the publication also disclosed donated study medication and industry relationships for some authors. For families, treatment changes require a discussion with the prescriber about the child's symptoms, nutrition and adverse effects. The National Institute of Mental Health advises against stopping prescribed mental health medication without professional guidance. [Trial publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7048642/) [NIMH medication guidance](https://www.nimh.nih.gov/health/topics/mental-health-medications)

Frequently Asked Questions

Contact the prescriber if appetite loss persists or weight gain slows. NICE lists dietary advice, meal timing and clinician-planned medication changes among possible responses. Agree on any treatment break with the prescribing clinician.

Yes. CDC guidance describes medication and behavioral treatment together for children aged six and older. For children younger than six, parent training in behavior management is recommended before medication is tried.

Not necessarily. In the 2020 randomized trial, weight gain improved without a measurable increase in height growth rate during the evaluated period. Continued monitoring is needed to assess an individual child's growth.

References

  1. Centers for Disease Control and Prevention. Treatment of ADHD. [Clinical information](https://www.cdc.gov/adhd/treatment/).
  2. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. Guideline NG87, recommendations 1.8.5–1.8.9. [Maintenance and monitoring](https://www.nice.org.uk/guidance/ng87/chapter/recommendations#maintenance-and-monitoring).
  3. Waxmonsky JG, et al. A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. Journal of the American Academy of Child & Adolescent Psychiatry. 2020;59(12):1330–1341. [doi:10.1016/j.jaac.2019.08.472](https://doi.org/10.1016/j.jaac.2019.08.472).
  4. National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder: What You Need to Know. [ADHD information](https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know).
  5. National Institute of Mental Health. Mental Health Medications. [Medication guidance](https://www.nimh.nih.gov/health/topics/mental-health-medications).